Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.39 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637853 | 0.83 | TGFBR1 (0.57) | DYRK1ATGFBR1PFKFB3BMPR1ASMAD2 | |
| SCHEMBL15638539 | 0.82 | DYRK1A (0.41) | DYRK1ATGFBR1ADORA2APFKFB3BMPR1A | |
| SCHEMBL15637978 | 0.82 | PFKFB3 (0.46) | DYRK1ATGFBR1ADORA2APFKFB3BMPR1A | |
| SCHEMBL15638051 | 0.81 | DYRK1A (0.50) | DYRK1AADORA1TGFBR1ADORA2APFKFB3 | |
| SCHEMBL18041549 | 0.78 | TGFBR1 (0.44) | DYRK1ATGFBR1BMPR1ASMAD2MAP4K4 | |
| SCHEMBL18057149 | 0.77 | MAPT (0.49) | DYRK1ATGFBR1PFKFB3BMPR1ASMAD2 | |
| SCHEMBL24716156 | 0.75 | ADORA1 (0.41) | DYRK1AADORA1TGFBR1ADORA2AMAP4K4 | |
| SCHEMBL15638536 | 0.74 | RIPK1 (0.43) | DYRK1ATGFBR1ADORA2APFKFB3BMPR1A | |
| SCHEMBL18041624 | 0.74 | TGFBR1 (0.63) | TGFBR1BMPR1ASMAD2MAPK14 | |
| SCHEMBL29677066 | 0.73 | TGFBR1 (0.67) | DYRK1ATGFBR1ADORA2ABMPR1ASMAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| EP-2903978-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | claimed |
| WO-2014055955-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| CN-106536507-B | 2, 3-disubstituted pyridine compounds as TGF- β inhibitors and methods of use thereof | 里格尔药品股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2903978-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2014055955-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | DYRK1A 4041/4885ADORA1 1930/4885TGFBR1 128/4885 |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | DYRK1A 3406/4885ADORA1 1995/4885TGFBR1 1/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | DYRK1A 2300/4885ADORA1 2057/4885TGFBR1 2/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | DYRK1A 2482/4885ADORA1 2077/4885TGFBR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.